Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza

Pandemic influenza A virus (IAV) remains a significant threat to global health. Preparedness relies primarily upon a single class of neuraminidase (NA) targeted antivirals, against which resistance is steadily growing. The M2 proton channel is an alternative clinically proven antiviral target, yet a...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, Claire, Kankanala, Jayakanth, Foster, Toshana L., Goldhill, Daniel H., Bao, Peng, Simmons, Katie, Pingen, Marieke, Bentham, Matthew, Atkins, Elizabeth, Loundras, Eleni, Elderfield, Ruth, Claridge, Jolyon K., Thompson, Joseph, Stilwell, Peter R., Tathineni, Ranjitha, McKimmie, Clive S., Targett-Adams, Paul, Schnell, Jason R., Cook, Graham P., Evans, Stephen, Barclay, Wendy S., Foster, Richard, Griffin, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418971/
https://www.ncbi.nlm.nih.gov/pubmed/32780760
http://dx.doi.org/10.1371/journal.ppat.1008716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418971/
https://www.ncbi.nlm.nih.gov/pubmed/32780760
http://dx.doi.org/10.1371/journal.ppat.1008716

Ejemplares similares